Vanda Pharmaceuticals (VNDA) Expected to Announce Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, July 31st. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.34) per share and revenue of $54.77 million for the quarter. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.05. The company had revenue of $50.04 million for the quarter, compared to analysts' expectations of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 21.98% and a negative return on equity of 8.30%. On average, analysts expect Vanda Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vanda Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ:VNDA traded down $0.05 on Friday, reaching $4.74. 401,037 shares of the company's stock were exchanged, compared to its average volume of 447,410. The firm has a market capitalization of $279.33 million, a price-to-earnings ratio of -6.32 and a beta of 0.68. Vanda Pharmaceuticals has a fifty-two week low of $3.81 and a fifty-two week high of $6.26. The business's 50-day moving average is $4.62 and its two-hundred day moving average is $4.54.

Insider Transactions at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The shares were acquired at an average price of $4.40 per share, with a total value of $44,000.00. Following the acquisition, the chief executive officer directly owned 2,325,731 shares in the company, valued at approximately $10,233,216.40. The trade was a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the transaction, the director owned 97,082 shares of the company's stock, valued at $445,606.38. This represents a 6.73% decrease in their position. The disclosure for this sale can be found here. 10.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. Royal Bank of Canada boosted its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 34.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,713 shares of the biopharmaceutical company's stock after buying an additional 14,232 shares during the period. Royal Bank of Canada owned 0.09% of Vanda Pharmaceuticals worth $256,000 at the end of the most recent quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. Finally, Wall Street Zen raised shares of Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 14th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.